Clopidogrel Tablet
Product Images NDC 42543-714

This is a description for Clopidogrel bisulfate tablets. The tablets come in a bottle with 30 tablets, with each tablet containing 391.5 mg of Clopidogrel bisulfate, which is equivalent to 300mg of Clopidogrel base. There are dosage instructions inside the package. The tablets should be stored at room temperature: 20°C to 25°C (68°F to 77°F), with excursions being permitted to 15°C to 30°C (59°F to 86°F). Vensun Pharmaceuticals, Inc. manufactures the tablets. The pharmaceutical company has its address in Yardley, PA 19067. The accompanying Medication Guide should be dispensed to each patient by the pharmacist.*

Clopidogrel is a medication sold in the form of tablets. Each tablet consists of 97.875mg of Clopidogrel bisulfate, which is equal to 75mg of clopidogrel base. The usual adult dosage is provided in the package insert for full prescribing information. The medication must be stored at 20° to 25°C (68° to 77°F); excursions are allowed to 15° to 30°C (59° to 86°F) as specified by the USP Controlled Room Temperature. The tablets are manufactured by ScieGen Pharmaceuticals, Inc. and distributed by Vensun Pharmaceuticals, Inc. in Yardley, PA 19067. The drug is only available via prescription and pharmacists should provide the accompanying medication guide to each patient.*

This is a figure showing the exposure to Clopidogrel active metabolite after multiple doses of Clopidogrel 75 mg alone or with Proton Pump Inhibitors (PPIs). The figure displays the effect of co-administered PPI on the active metabolite AUC, with mean and 90% confidence interval values. The PPIs shown in the figure are Deslansoprazole, Lansoprszole, Pantoprazole, and Omeprazole. The figure also displays the change relative to clopidogrel administered alone.*

This appears to be a chart or graph displaying cumulative event rates of cardiovascular death, myocardial infarction, and stroke for a study comparing a placebo with aspirin to clopidogrel with aspirin. The graph shows that the cumulative event rate is significantly lower with clopidogrel and aspirin compared to the placebo and aspirin combination. The study followed up for a period of 12 months and utilized other standard therapies as well.*

The text describes the results of the COMMIT study, showing the cumulative event rates of death for patients given either a placebo or clopidogrel, measured before first discharge. The table indicates that 1845 patients given the placebo died, equivalent to 8.1%, compared to 7.5% (1726 patients) for those given clopidogrel, indicating a 7% proportional risk reduction (with a p-value of 0.03). The graph shows these figures over time, measured in days since randomization up to 28 days. The study notes that all treated patients received aspirin.*

This text appears to be data related to a clinical trial comparing the effectiveness of Placebo and Clopidogrel for reducing the risk of death, re-infarction or stroke. The data suggests that Clopidogrel resulted in a 9% reduction in proportional risk compared to Placebo, with 9.2% of participants experiencing an event while taking Clopidogrel, and 10.1% experiencing an event while taking Placebo. The trial lasted up to 28 days and had a p-value of 0.002 for the reduction in risk of death. The text also provides a timeline graph of the trial with days since randomization along the X-axis and the number of events occurring at each time point.*

The text is presenting the data about the effects of adding the drug Clopidogrel to Aspirin on the combined primary endpoint across baseline and concomitant medication subgroups for the COMMIT study. However, due to the incomplete nature of the text obtained, it is not possible to derive any useful insights.*

This appears to be a chart or graph displaying the cumulative event rate for fatal or non-fatal vascular events over a period of up to 24 months of follow-up. The data is presented for two treatments, aspirin and clopidogrel, with the months of follow-up represented on the x-axis and the cumulative event rate as a percentage on the y-axis. The chart also includes labels for the total number of events (represented by "n") and some unidentified symbols (@ and &).*